公开(公告)号：US20220380355A1

公开(公告)日：2022-12-01

申请号：US17762771

申请日：2020-10-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jie Chen ,  Carolyn Diane Dzierba ,  Junqing Goo ,  Amy C. Hart ,  William J. Pitts ,  Sing-Yuen Sit

IPC: C07D409/04 ,  C07D417/04 ,  C07D403/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11440913B2

公开(公告)日：2022-09-13

申请号：US16758892

申请日：2018-10-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Michael E. Mertzman ,  Carolyn Diane Dzierba ,  Jason M. Guernon ,  Amy C. Hart ,  Guanglin Luo ,  John E. Macor ,  William J. Pitts ,  Jianliang Shi ,  Steven H. Spergel

IPC: A61K31/5025 ,  C07D487/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US10301306B2

公开(公告)日：2019-05-28

申请号：US15527343

申请日：2015-12-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Amy C. Hart ,  William J. Pitts ,  Harold Mastalerz ,  Junqing Guo ,  Gregory D. Brown

IPC: C07D471/04

Abstract: Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein.

公开(公告)号：US20180370956A1

公开(公告)日：2018-12-27

申请号：US16009389

申请日：2018-06-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Rajeev S. BHIDE ,  John V. Duncia ,  John Hynes ,  Satheesh K. Nair ,  William J. Pitts ,  Sreekantha Ratna Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Kumar Sistla ,  Hong Wu

IPC: C07D407/14 ,  C07D405/14 ,  C07D405/12 ,  C07D213/74 ,  C07D401/14 ,  C07D417/14 ,  C07D401/12

Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

公开(公告)号：US20150284382A1

公开(公告)日：2015-10-08

申请号：US14441705

申请日：2013-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Rajeev S. Bhide ,  John V. Duncia ,  John Hynes ,  Satheesh K. Nair ,  William J. Pitts ,  Sreekantha R. Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Sistla ,  Hong Wu

IPC: C07D417/14 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D213/74 ,  C07D401/12

CPC classification number: C07D407/14 ,  C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/14

Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是单环杂芳基，且R 1，R 3，R 4，R 5和R 6如本文所定义，可用作激酶调节剂，包括IRAK -4抑制。

公开(公告)号：US12275721B2

公开(公告)日：2025-04-15

申请号：US17762771

申请日：2020-10-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jie Chen ,  Carolyn Diane Dzierba ,  Junqing Guo ,  Amy C. Hart ,  William J. Pitts ,  Sing-Yuen Sit

IPC: C07D409/04 ,  C07D403/04 ,  C07D417/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20250074909A1

公开(公告)日：2025-03-06

申请号：US18928275

申请日：2024-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20230020273A1

公开(公告)日：2023-01-19

申请号：US17289269

申请日：2019-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  William J. Pitts ,  Michael E. Mertzman ,  Ryan M. Moslin ,  Trevor C. Sherwood ,  John L. Gilmore ,  Alaric J. Dyckman

IPC: C07D413/14 ,  C07B59/00 ,  C07D403/12 ,  C07D413/12 ,  C07D417/14 ,  C07D417/12 ,  C07D401/14 ,  C07D403/14

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US10913738B2

公开(公告)日：2021-02-09

申请号：US16484604

申请日：2018-02-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04 ,  A61P29/00 ,  A61P19/02 ,  A61P17/06 ,  A61P1/00

Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

公开(公告)号：US20180072712A1

公开(公告)日：2018-03-15

申请号：US15818826

申请日：2017-11-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/14 ,  C07D487/04 ,  C07D471/04 ,  C07D413/14 ,  C07D417/04 ,  C07D413/04

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.